Shares of Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $24.99 and traded as low as $21.28. Hikma Pharmaceuticals shares last traded at $21.28, with a volume of 12,205 shares changing hands.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on HKMPF. Jefferies Financial Group cut Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. Morgan Stanley lifted their price target on Hikma Pharmaceuticals from GBX 1,800 ($22.10) to GBX 1,900 ($23.33) in a research note on Friday, August 4th. JPMorgan Chase & Co. increased their price objective on Hikma Pharmaceuticals from GBX 2,100 ($25.79) to GBX 2,350 ($28.86) in a research note on Friday, August 18th. Royal Bank of Canada downgraded shares of Hikma Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Wednesday, September 6th. Finally, Berenberg Bank increased their price target on shares of Hikma Pharmaceuticals from GBX 1,740 ($21.37) to GBX 2,100 ($25.79) in a research report on Monday, August 7th.
Hikma Pharmaceuticals Stock Performance
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.
- Five stocks we like better than Hikma Pharmaceuticals
- How to Invest in the Best Canadian Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in Biotech Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.